NCT06979180View on ClinicalTrials.gov

A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on the Regression of Abnormal Cervical Cells Caused by HPV.

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
CIN - Cervical Intraepithelial NeoplasiaCIN 1CIN 2HPVCervical Cells
Interventions
DIETARY_SUPPLEMENT

Papillex®

Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.

OTHER

Placebo

Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.

Trial Locations (1)

N5Y 5V6

RECRUITING

KGK Science Inc., London

Sponsors

Lead Sponsor

Papillex Inc.
All Listed Sponsors
lead

Papillex Inc.

INDUSTRY

NCT06979180 - A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on the Regression of Abnormal Cervical Cells Caused by HPV. | Biotech Hunter | Biotech Hunter